Form 4: Eli Lilly Executive Sells Shares Under 10b5-1 Plan

Eli Lilly & Co. EVP Ilya Yuffa reported the sale of 2,500 shares of common stock for $1,150.77 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Ilya Yuffa, Executive Vice President and President of LLY USA & Global Capabilities at Eli Lilly & Co. (LLY), reported a transaction involving common stock.
• The transaction, dated June 10, 2026, involved the sale of 2,500 shares.
• The sale price was $1,150.77 per share, totaling $2,876,925.
• This transaction was executed as part of a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2026.
• Following the transaction, Yuffa beneficially owns 29,804.111 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an executive sale can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic trading based on non-public information.

Negatives

• Executive sale of company stock, though conducted under a pre-planned 10b5-1, can sometimes be perceived negatively by the market.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The Rule 10b5-1 plan indicates a pre-determined strategy for future transactions.

Industry Context

StockSavvy.ai notes that insider sales, even when executed under a Rule 10b5-1 plan, are closely watched by investors. Eli Lilly (LLY) operates in the highly competitive pharmaceutical industry, where executive compensation and stock ownership are common. The price of $1,150.77 per share reflects the significant valuation of the company.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal, though mitigated by the 10b5-1 plan. The sale does not directly impact the company's operations or financial health.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• Continued monitoring of insider transactions for any further sales or purchases by Eli Lilly executives.
• Observation of the company's stock performance and any market reaction to this transaction.

Key Dates

Keywords

Eli Lilly, LLY, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Beneficial Ownership, Executive Compensation